These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15841314)

  • 1. Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: an 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia.
    Ames PR; Ciampa A; Margaglione M; Scenna G; Iannaccone L; Brancaccio V
    Thromb Haemost; 2005 Apr; 93(4):694-9. PubMed ID: 15841314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study.
    Hering D; Piper C; Bergemann R; Hillenbach C; Dahm M; Huth C; Horstkotte D
    Chest; 2005 Jan; 127(1):53-9. PubMed ID: 15653962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome.
    Ames PR; Margaglione M; Ciampa A; Colaizzo D; Ferrara F; Iannaccone L; Vincenzobrancaccio
    Thromb Res; 2011 Jun; 127(6):595-9. PubMed ID: 21371740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is early antithrombotic therapy necessary after tissue mitral valve replacement?
    Colli A; D'Amico R; Mestres CA; Pomar JL; Cámara ML; Ruyra X; Mulet J
    J Heart Valve Dis; 2010 Jul; 19(4):405-11. PubMed ID: 20845885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome.
    Della Valle P; Crippa L; Garlando AM; Pattarini E; Safa O; Viganò D'Angelo S; D'Angelo A
    Haematologica; 1999 Dec; 84(12):1065-74. PubMed ID: 10586206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieved anticoagulation vs prosthesis selection for mitral mechanical valve replacement: a population-based outcome study.
    Le Tourneau T; Lim V; Inamo J; Miller FA; Mahoney DW; Schaff HV; Enriquez-Sarano M
    Chest; 2009 Dec; 136(6):1503-1513. PubMed ID: 19482955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5.
    Ruiz-Irastorza G; Khamashta MA; Hunt BJ; Escudero A; Cuadrado MJ; Hughes GR
    Arch Intern Med; 2002 May; 162(10):1164-9. PubMed ID: 12020188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.
    Crowther MA; Ginsberg JS; Julian J; Denburg J; Hirsh J; Douketis J; Laskin C; Fortin P; Anderson D; Kearon C; Clarke A; Geerts W; Forgie M; Green D; Costantini L; Yacura W; Wilson S; Gent M; Kovacs MJ
    N Engl J Med; 2003 Sep; 349(12):1133-8. PubMed ID: 13679527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
    Danowski A; de Azevedo MN; de Souza Papi JA; Petri M
    J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute physical exercise is safe in patients with primary antiphospholipid syndrome with exclusive venous thrombosis and under oral anticoagulation with warfarin.
    Garcia CB; Seguro LP; Perandini LA; de Sá Pinto AL; Lima FR; Negrão CE; Bonfa E; Borba EF
    Rheumatol Int; 2014 Dec; 34(12):1737-41. PubMed ID: 24825252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Severe, non-infectious mitral valve endocarditis after mitral valve reconstruction in a 32-year old female with primary antiphospholipid syndrome].
    Herrmann M; Keysser G; Seige M; Holzhausen HJ; Silber RE; Diez C
    Z Kardiol; 2004 Jul; 93(7):546-54. PubMed ID: 15243766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the "LOWERING-IT" Trial.
    Torella M; Torella D; Chiodini P; Franciulli M; Romano G; De Santo L; De Feo M; Amarelli C; Sasso FC; Salvatore T; Ellison GM; Indolfi C; Cotrufo M; Nappi G
    Am Heart J; 2010 Jul; 160(1):171-8. PubMed ID: 20598989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. North American multicenter experience with the On-X prosthetic heart valve.
    McNicholas KW; Ivey TD; Metras J; Szentpetery S; Marra SW; Masters RG; Dilling EW; Slaughter MS; Mack MJ
    J Heart Valve Dis; 2006 Jan; 15(1):73-8; discussion 79. PubMed ID: 16480015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombo-embolic and bleeding complications in patients with mechanical valve replacements--a prospective observational study.
    Schapkaitz E; Jacobson BF; Becker P; Conway G
    S Afr Med J; 2006 Aug; 96(8):710-3. PubMed ID: 17019493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome.
    Hernández-Molina G; Espericueta-Arriola G; Cabral AR
    Clin Exp Rheumatol; 2013; 31(3):382-8. PubMed ID: 23305633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).
    Finazzi G; Marchioli R; Brancaccio V; Schinco P; Wisloff F; Musial J; Baudo F; Berrettini M; Testa S; D'Angelo A; Tognoni G; Barbui T
    J Thromb Haemost; 2005 May; 3(5):848-53. PubMed ID: 15869575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thromboembolic and bleeding complications in patients treated with oral anticoagulant therapy after mechanical heart valve prostheses implantation].
    Kanaoka Y; Tanemoto K; Murakami T; Kuroki K
    Kyobu Geka; 2000 Aug; 53(9):754-8. PubMed ID: 10935402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INR self-management permits lower anticoagulation levels after mechanical heart valve replacement.
    Koertke H; Minami K; Boethig D; Breymann T; Seifert D; Wagner O; Atmacha N; Krian A; Ennker J; Taborski U; Klövekorn WP; Moosdorf R; Saggau W; Koerfer R
    Circulation; 2003 Sep; 108 Suppl 1():II75-8. PubMed ID: 12970212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aniticoagulation in patients following prosthetic heart valve replacement.
    Akhtar RP; Abid AR; Zafar H; Khan JS
    Ann Thorac Cardiovasc Surg; 2009 Feb; 15(1):10-7. PubMed ID: 19262444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose international normalized ratio self-management: a promising tool to achieve low complication rates after mechanical heart valve replacement.
    Koertke H; Zittermann A; Minami K; Tenderich G; Wagner O; El-Arousy M; Krian A; Ennker J; Taborski U; Klövekorn WP; Moosdorf R; Saggau W; Morshuis M; Koerfer J; Seifert D; Koerfer R
    Ann Thorac Surg; 2005 Jun; 79(6):1909-14; discussion 1914. PubMed ID: 15919283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.